Shandong Jincheng Pharmaceutical Group Co., Ltd (SHE:300233)
China flag China · Delayed Price · Currency is CNY
11.33
-0.21 (-1.82%)
Nov 13, 2026, 1:55 PM CST

SHE:300233 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
2,8182,7203,3533,5213,4843,127
Other Revenue
16.8316.8320.1817.6621.4611.78
2,8342,7373,3733,5383,5063,138
Revenue Growth
1.59%-18.87%-4.66%0.93%11.70%5.96%
Cost of Revenue
1,9141,8122,0702,0731,9321,542
Gross Profit
920.66924.481,3041,4651,5741,597
Selling, General & Admin
501.76618.74842.741,035996.391,168
Research & Development
192.06188.46170.34184.71171.1178.34
Other Operating Expenses
32.5230.6827.8122.532.7930.74
Operating Expenses
735.92838.271,0381,2451,2001,373
Operating Income
184.7486.21265.27219.96373.34223.97
Interest Expense
-7.9-10.81-18.48-24.92-26.82-27.04
Interest & Investment Income
30.229.3712.915.1815.724.54
Currency Exchange Gain (Loss)
-0.53-0.537.581.340.97-10.1
Other Non Operating Income (Expenses)
-5.892.75-2.2-3.32-2.52-4.49
EBT Excluding Unusual Items
200.6486.99265.08208.23360.66206.89
Gain (Loss) on Sale of Investments
-0.07-0.09-1.58-0.08-12.6-1.13
Gain (Loss) on Sale of Assets
51.583.23.37-1.981.531.18
Asset Writedown
-55.73-24.12-16.45-2.66-21.32-39.23
Other Unusual Items
12.0312.0318.0221.917.728.84
Pretax Income
208.4478.02268.45225.41345.97196.55
Income Tax Expense
54.0635.7560.7132.160.0973.47
Earnings From Continuing Operations
154.3942.27207.74193.31285.88123.08
Minority Interest in Earnings
2.761.91-10.95-18.6-12.51-15.1
Net Income
157.1544.19196.78174.71273.37107.98
Net Income to Common
157.1544.19196.78174.71273.37107.98
Net Income Growth
103.28%-77.55%12.63%-36.09%153.15%-
Shares Outstanding (Basic)
357368378388385386
Shares Outstanding (Diluted)
357368378388385386
Shares Change
-8.63%-2.70%-2.53%0.84%-0.17%-0.60%
EPS (Basic)
0.440.120.520.450.710.28
EPS (Diluted)
0.440.120.520.450.710.28
EPS Growth
122.49%-76.92%15.56%-36.62%153.57%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
314.86218.76153.97321.18-118.0461.04
Free Cash Flow Per Share
0.880.590.410.83-0.310.16
Dividend Per Share
0.1500.2500.2500.2000.1500.198
Dividend Growth
-40.00%0%25.00%33.33%-24.31%-1.82%
Gross Margin
32.48%33.78%38.65%41.40%44.89%50.87%
Operating Margin
6.52%3.15%7.86%6.22%10.65%7.14%
Profit Margin
5.54%1.61%5.83%4.94%7.80%3.44%
Free Cash Flow Margin
11.11%7.99%4.56%9.08%-3.37%1.94%
EBITDA
505.35405.21582.11525.43624.67443.16
EBITDA Margin
17.83%14.80%17.26%14.85%17.82%14.12%
D&A For EBITDA
320.61318.99316.84305.48251.33219.18
EBIT
184.7486.21265.27219.96373.34223.97
EBIT Margin
6.52%3.15%7.86%6.22%10.65%7.14%
Effective Tax Rate
25.93%45.82%22.62%14.24%17.37%37.38%
Revenue as Reported
2,8342,7373,3733,5383,5063,138
Advertising Expenses
---173.31198.82-